Lyudmila A. Bazhenova, MD
Alectinib (Alecensa) is the frontline de-facto standard of care for patients with ALK
-positive non–small cell lung cancer (NSCLC), said Lyudmila A. Bazhenova, MD. Exploration into mechanisms of resistance will help physicians unveil how to best sequence available therapies.
OncLive: Please discuss the recent questions in ALK-positive NSCLC.
My lecture about ALK
-positive lung cancer concentrates on sequencing strategies. We now have more than 1 ALK inhibitor approved in lung cancer. The common questions that come up are, “How do we sequence them? What is the right first-line and second-line ALK inhibitor?” And [we need to know] whether you need to do a postprogression biopsy to understand the mechanism of resistance to ALK inhibition.
... to read the full story